Leading drug maker Glenmark Pharmaceuticals has set up a new sales marketing arm in Poland.


</p><tr><td><p class='TableClas'></p><P class='TableClas'> <DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>The company has acquired seven established medicine <BR>brands from Iceland drug major Actavis to kick start its polish operations.</P>
</p><p class='TableClas'>The deal has been carried out through Glenmark's Czech subsidiary <BR>Medicamenta which acquired seven brands from Actavis and Biovena (an <BR>affiliate of Actavis in Poland) for an undisclosed sum.</P>
</p><p class='TableClas'>Glenn Saldanha, managing director and CEO, Glenmark said that the portfolio <BR>acquisition will "accelerate growth in a very promising central and east <BR>european market".</P></p></table>


Glenmark sets up sales marketing arm in Poland

Also Read

Aditya Birla group's cement production up 2.20%

FDC gets approval for Ciprofloxacin solution

NYSE Euronext acquires 5 % equity in MCX

Shri Lakshmi plans Rs 350 crore capex

P&G sets up R&D centre in Bangalore

Explore News